All In MedTech

Device Trial Radar · NCT02873312

Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial

Prospective, Multi-Center, Randomized, Double-Blinded Trial of Percutaneous Tibial Nerve Stimulation With the Bioness StimRouter Neuromodulation System Versus Sham in the Treatment of Overactive Bladder (OAB)

Last checked: Nov 20, 2026Latest source record: Jan 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

180

Planned (sponsor's estimate)

Start

Feb 10, 2017

Primary completion

Jul 30, 2021

Study completion Jul 30, 2021

Sponsor

Lead sponsor
Bioness IncNot on our public-company list
Sponsor type
Industry
First posted
Aug 19, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Approximately 20 Study Sites will participate over total 24 months. Study population will consist of adults age 22 or over, reporting overactive bladder (OAB) symptoms for at least 3 months. Primary Study Objectives: 1. To assess efficacy of the StimRouter stimulation in improving OAB symptoms of urgency and frequency as measured by Patient Voiding Diary when targeting the posterior tibial nerve 2. To assess safety of the StimRouter therapy for the indication of OAB Secondary Study Objective: To evaluate efficacy of the StimRouter therapy in addressing urinary urge incontinence as measured by the Patient Voiding Diary Study Design is prospective, multi-center, randomized, double-blinded Primary Endpoint: The primary efficacy endpoint will be the difference between the investigational and control groups in proportion of responders, where Responder is defined as having ≥50% improvement in average voiding frequency above the normal value of 8 (those returning to normal voiding based on 7-day average voids/leak episodes \< 9, will be categorized as achieving half or more reduction) AND having ≥50% improvement in average number of moderate to severe urgency episodes, at approximately three months after programming. Secondary Endpoint: Secondary endpoint will be the difference between the investigational and control groups in proportion of patients with reduction by half or more in urinary urge incontinence as measured by the average number of urge incontinence episodes per day.

Conditions

  • Overactive Bladder

Interventions

  • StimRouterDevice

    The StimRouter System is a neuromodulation system consisting of the following components and accessories: * An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead. * An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories. * A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1) Patient Voiding DiaryTime frame: Baseline, Month 3
  2. Adverse Events reported cumulatively throughout studyTime frame: Baseline through Month 6

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Del Sol Research

    Tucson, Arizona · Withdrawn

  • Kaiser Permanente Reserach

    Irvine, California · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

16 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.